EichorEICHOR
Condition: Alk Positive Non Small Cell Lung Cancer Nsclc Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Alk Positive Non Small Cell Lung Cancer Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07354061Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05498064Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Pingping Song · NCT05765877Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3 · 157 location(s) · Nuvalent Inc. · NCT06765109Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Phase N/A · 1 location(s) · Peking University Shenzhen Hospital · NCT07374614Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Phase 2 · 1 location(s) · Guangdong Association of Clinical Trials · NCT06092086A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Phase 1/Phase 2 · 12 location(s) · TRIANA Biomedicines, Inc. · NCT07491497Alectinib Pharmacokinetic in Patients With NSCLC
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05713006Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Ther
Phase N/A · 44 location(s) · Hoffmann-La Roche · NCT06862869A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT05241028Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Phase N/A · 1 location(s) · Sichuan Cancer Hospital and Research Institute · NCT06361589Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Phase 3 · 1 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT05341583A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small
Phase 2 · 9 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06378892Gilteritinib for the Treatment of ALK NSCLC
Phase 1 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT06225427Patient-centered, Optimal Integration of Survivorship and Palliative Care
NA · 1 location(s) · Massachusetts General Hospital · NCT04900935Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World C
NA · 31 location(s) · Pfizer · NCT06487078Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07415005
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.